AIGH Capital Management LLC Takes $4.46 Million Position in AngioDynamics, Inc. (NASDAQ:ANGO)

AIGH Capital Management LLC acquired a new stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 474,488 shares of the medical instruments supplier's stock, valued at approximately $4,455,000. AngioDynamics comprises approximately 1.8% of AIGH Capital Management LLC's holdings, making the stock its 19th biggest position. AIGH Capital Management LLC owned 1.17% of AngioDynamics at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Bank of New York Mellon Corp grew its holdings in shares of AngioDynamics by 3.2% during the fourth quarter. Bank of New York Mellon Corp now owns 122,676 shares of the medical instruments supplier's stock valued at $1,124,000 after buying an additional 3,815 shares during the last quarter. Squarepoint Ops LLC bought a new position in shares of AngioDynamics during the 4th quarter worth approximately $387,000. Ameriprise Financial Inc. lifted its position in shares of AngioDynamics by 24.0% during the 4th quarter. Ameriprise Financial Inc. now owns 277,565 shares of the medical instruments supplier's stock worth $2,542,000 after buying an additional 53,675 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of AngioDynamics by 1,281.4% during the 1st quarter. GAMMA Investing LLC now owns 13,897 shares of the medical instruments supplier's stock worth $130,000 after buying an additional 12,891 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in AngioDynamics by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 329,090 shares of the medical instruments supplier's stock valued at $3,014,000 after acquiring an additional 2,270 shares during the last quarter. 89.43% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Canaccord Genuity Group set a $17.00 price objective on shares of AngioDynamics and gave the company a "buy" rating in a research note on Wednesday, July 16th. Lake Street Capital began coverage on shares of AngioDynamics in a research note on Wednesday, July 16th. They issued a "buy" rating and a $24.00 price objective for the company. Finally, HC Wainwright reiterated a "buy" rating and issued a $16.00 target price on shares of AngioDynamics in a research note on Wednesday, July 16th.

AngioDynamics Trading Up 1.3%

Shares of ANGO traded up $0.12 during mid-day trading on Tuesday, reaching $9.11. 244,093 shares of the stock traded hands, compared to its average volume of 589,635. The firm has a fifty day moving average price of $9.84 and a 200 day moving average price of $10.08. The company has a market cap of $370.00 million, a price-to-earnings ratio of -10.98 and a beta of 0.60. AngioDynamics, Inc. has a 1 year low of $5.83 and a 1 year high of $13.50.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its quarterly earnings data on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.09. The firm had revenue of $80.16 million for the quarter, compared to analysts' expectations of $74.26 million. AngioDynamics had a negative return on equity of 3.20% and a negative net margin of 11.62%. The company's revenue for the quarter was up 13.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.06) earnings per share. On average, sell-side analysts anticipate that AngioDynamics, Inc. will post -0.37 EPS for the current year.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.